Loading clinical trials...
Loading clinical trials...
A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Conditions
Interventions
ASP1948
nivolumab
+1 more
Locations
42
United States
Yale Center for Clinical Investigation
New Haven, Connecticut, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Cancer Center at Greater Baltimore Medical
Baltimore, Maryland, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Washington University
St Louis, Missouri, United States
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
Omaha, Nebraska, United States
Start Date
July 2, 2018
Primary Completion Date
March 27, 2023
Completion Date
March 27, 2023
Last Updated
November 1, 2024
NCT07177937
NCT07360314
NCT07403721
NCT07539285
NCT07524348
NCT03093116
Lead Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions